Description
The posttransplant administration of cyclophosphamide to prevent both graft-vs-host and hostvs-graft alloreactivity has revolutionized the practice of hematopoietic cell transplantation
(HCT). The eligibility boundaries for consideration of HCT have expanded, and now include
patients with a suitable haploidentical donor, instead of an HLA-identical sibling donor. This
case study provides not only a simulation of treatment choices for a patient with multiple
myeloma and end-stage renal disease, but also the background science that is helpful in
understanding the clinical situation.
AABB thanks Thomas Spitzer, MD, for development of this case study.
Reviews
There are no reviews yet.